Tag: CML

Biomarker, Innovation

Clinical Challenges: Discontinuing TKIs in Chronic Myeloid Leukemia

December 11, 2020

Via: MedPageToday

Treatment-free remission is now regarded as a primary aim of patients with long-term chronic myeloid leukemia (CML). Starting with the approval of imatinib in 2001, the effectiveness of tyrosine kinase inhibitors (TKIs) has resulted in significant improvements in outcomes for […]